Amgen Inc (AMGN) announced an update on their ongoing clinical study.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Amgen Inc. has launched a phase 1b study in small cell lung cancer that tests tarlatamab with ZL-1310, with or without an added immunotherapy drug. The trial aims to define safe dose levels, check early signs of benefit, and guide later phase trials that could expand Amgen’s lung cancer franchise if results are positive.
The study evaluates three drug combinations given by IV: tarlatamab, ZL-1310, and in one arm the anti–PD-L1 drug durvalumab. The goal is to find the right dose mix and see whether adding these agents together can improve outcomes beyond current standards in this aggressive cancer.
This is an interventional study with no placebo group, so all patients receive active treatment. It uses a stepwise, non-random setup to test doses in sequence, and the main aim is treatment, with a focus on safety rather than direct comparison between arms.
The trial was first submitted in April 2026, signaling the formal start of the program. The latest update in May 2026 shows the study is still recruiting, and key milestones such as primary and final completion will come later, which will mark when initial and full data sets are ready for review.
For investors, this update adds another early pipeline shot on goal for Amgen in lung cancer, building on tarlatamab’s profile. The study’s success could support longer-term growth and help Amgen compete with other oncology players, though near-term stock impact is likely modest until safety and early efficacy data emerge.
The study remains active and under recruitment, with ongoing updates and further details available on the ClinicalTrials portal.
To learn more about AMGN’s potential, visit the Amgen Inc drug pipeline page.